Wann kann nach einer Hirnblutung wieder mit einer Phenprocoumon-Therapie begonnen werden?

Literatur

• 1 Wijdicks E F, Schievink W I, Brown R D, Mullany C J. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves.  Neurosurgery. 1998;  42 769-773
• 2 Phan T G, Koh M, Wijdicks E F. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk.  Arch Neurol. 2000;  57 1710-1713
• 3 Bonow R O, Carabello B, de Leon A C, Edmunds L H, Fedderly B J, Freed M D, Gaasch W H, McKay C R, Nishimura R A, O’Gara P T, O’Rourke R A, Rahimtoola S H, Ritchie J L, Cheitlin M D, Eagle K A, Gardner T J, Garson A, Gibbons R J, Russell R O, Ryan T J, Smith S C. ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease . Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease).  J Heart Valve Dis. 1998;  7 672-707
• 4 Lev-Ran O, Kramer A, Gurevitch J, Shapira I, Mohr R. Low-molecular-weight heparin for prosthetic heart valves: treatment failure.  Ann Thorac Surg. 2000;  69 264-265